

# TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus

Cristiana Guiducci<sup>1</sup>, Mei Gong<sup>1</sup>, Zhaohui Xu<sup>2</sup>, Michelle Gill<sup>2†</sup>, Damien Chaussabel<sup>2</sup>, Thea Meeker<sup>1</sup>, Jean H. Chan<sup>1</sup>, Tracey Wright<sup>3,4</sup>, Marilyn Punaro<sup>3,4</sup>, Silvia Bolland<sup>5</sup>, Vassili Soumelis<sup>6</sup>, Jacques Banchereau<sup>2</sup>, Robert L. Coffman<sup>1</sup>, Virginia Pascual<sup>2,3</sup> & Franck J. Barrat<sup>1</sup>

Glucocorticoids are widely used to treat patients with autoimmune diseases such as systemic lupus erythematosus (SLE)<sup>1,2</sup>. However, regimens used to treat many such conditions cannot maintain disease control in the majority of SLE patients and more aggressive approaches such as high-dose methylprednisolone pulse therapy are used to provide transient reductions in disease activity<sup>3,4</sup>. The primary anti-inflammatory mechanism of glucocorticoids is thought to be NF- $\kappa$ B inhibition<sup>5</sup>. Recognition of self nucleic acids by toll-like receptors TLR7 and TLR9 on B cells and plasmacytoid dendritic cells (PDCs) is an important step in the pathogenesis of SLE<sup>6</sup>, promoting anti-nuclear antibodies and the production of type I interferon (IFN), both correlated with the severity of disease<sup>1,7</sup>. Following their activation by self-nucleic acid-associated immune complexes, PDCs migrate to the tissues<sup>8,9</sup>. **We demonstrate, *in vitro* and *in vivo*, that stimulation of PDCs through TLR7 and 9 can account for the reduced activity of glucocorticoids to inhibit the IFN pathway in SLE patients and in two lupus-prone mouse strains. The triggering of PDCs through TLR7 and 9 by nucleic acid-containing immune complexes or by synthetic ligands activates the NF- $\kappa$ B pathway essential for PDC survival. Glucocorticoids do not affect NF- $\kappa$ B activation in PDCs, preventing glucocorticoid induction of PDC death and the consequent reduction of systemic IFN- $\alpha$  levels. These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs.**

SLE is an autoimmune disease characterized by chronic stimulation of the innate immune system by endogenous nucleic acids<sup>1,6</sup>. SLE patients are often treated with strong immunosuppressive regimens, including cytotoxic drugs, antimalarial compounds and glucocorticoids<sup>1,2</sup>. Type I IFNs are central to disease pathogenesis; increased expression of IFN-regulated genes, termed the IFN-signature, correlates with autoantibodies and disease activity<sup>1,7</sup>. PDCs are the major source of IFN- $\alpha$  induced by nucleic acid-containing immune complexes<sup>6</sup>. Once activated by self DNA/chromatin or small nuclear ribonucleoprotein particle (snRNP)-containing immune complex<sup>6</sup>, PDCs migrate from the blood into inflamed tissues including the skin<sup>8</sup> and kidney<sup>9</sup>.

Glucocorticoids have strong anti-inflammatory effects on both acquired and innate immune functions. They inhibit B and T cell responses and effector functions of monocytes and neutrophils. At the cellular level, glucocorticoids inhibit NF- $\kappa$ B activity, thought to be the main mechanism by which glucocorticoids exert their anti-inflammatory effects<sup>5</sup>. In lupus, glucocorticoids are typically


administered orally on a daily basis, as the typical every other day regimens cannot maintain disease control. When doses greater than 40 mg per day are required, patients receive intravenous methylprednisolone (Solu-Medrol) pulse therapy (30 mg kg<sup>-1</sup> up to 1 g day<sup>-1</sup>). Such treatment can transiently reduce disease activity, but often does not induce remission or prevent end organ damage<sup>2-4</sup>. The reason why treatment of SLE requires much higher glucocorticoid doses than many other autoimmune diseases is not clear.

Lupus patients without treatment or with maintenance hydroxychloroquine (HCQ) treatment (200–400 mg day<sup>-1</sup>) display characteristic transcriptional changes in their blood cells (Fig. 1a, left). These changes can be analysed using ‘modules’ of transcriptionally co-regulated genes<sup>10</sup>. Multiple transcriptional modules normalize in patients receiving oral glucocorticoids (5–20 mg day<sup>-1</sup>) and/or mycophenolate mofetil (Fig. 1a), reflecting the strong immunosuppressive effect of glucocorticoids. However, the IFN pathway is not affected in patients treated by oral glucocorticoids (Fig. 1a and 71 SLE patients summarized in Fig. 1c). Consistent with this, glucocorticoids do not significantly reduce the production of IFN- $\alpha$  upon PDC activation with the TLR7 and 9 ligands influenza virus (FLU) or a CpG-containing immunostimulatory sequence (CpG-ISS), or with immune complexes from SLE patients (Fig. 1b and Supplementary Fig. 1a). This was confirmed by IFN- $\alpha$  protein levels (Supplementary Fig. 2b). Addition of a bifunctional TLR7 and 9 inhibitor, called immunoregulatory sequence (IRS, dashed line)<sup>11</sup> however, was effective at blocking IFN- $\alpha$  production (Fig. 1b and Supplementary Fig. 1a).

In contrast, intravenous pulse therapy can normalize the IFN signature (Fig. 1a, c). This correlates with a reduction in PDCs (Fig. 1c) but not other cells, such as CD14<sup>+</sup> monocytes, in the blood (Fig. 1c). Similar reduction of PDCs is observed in healthy donors but at much lower glucocorticoid doses (15 mg day<sup>-1</sup>)<sup>12</sup>, indicating that continuous triggering of TLR7 and 9 on PDCs by immune complexes in SLE patients counteracts the activity of glucocorticoids on the IFN pathway. The partial reduction in PDC numbers with oral glucocorticoid treatment did not significantly affect IFN module expression, which includes 36 type-I-IFN-inducible transcripts. The inhibition of the IFN-signature by pulse therapy is transient, returning to pre-pulse levels by day 8 (Fig. 1e and Supplementary Fig. 1b). Similarly, the number of PDCs is markedly reduced 1 day after pulse therapy but rebounds by day 6 (Fig. 1d, e).

Glucocorticoids induce apoptosis in many cell types<sup>13</sup>, including PDCs, where TLR signalling confers partial protection<sup>14</sup>. Freshly isolated PDCs from healthy donors stimulated with TLR7 or TLR9


<sup>1</sup>Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA. <sup>2</sup>Baylor Institute for Immunology Research, Dallas, Texas 75204, USA. <sup>3</sup>Texas Scottish Rite Hospital, Dallas, Texas 75219, USA. <sup>4</sup>University of Texas, Southwestern Medical Center and Children's Medical Center, Dallas, Texas 75235, USA. <sup>5</sup>Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA, USA. <sup>6</sup>Institut Curie, Department of Immunology, 26 rue d'Ulm, 75005 Paris, France. <sup>†</sup>Present address: University of Texas, Southwestern Medical Center, Dallas, Texas 75235, USA.



consecutive doses,  $n = 6$ ). Middle and lower panels: blood PDC and monocyte numbers in SLE patients untreated ( $n = 13$ ), on 5–10 mg daily oral glucocorticoids ( $n = 27$ ), oral daily glucocorticoids 20–30 mg ( $n = 16$ ) and the day after intravenous pulse ( $n = 6$ ). NS, not significant.

**d**, Representative flow cytometry analysis of PDCs before and 1 and 6 days after intravenous pulse. **e**, Top: quantification of the average interferon module level expression (Nanostring, see Supplementary Fig. 1) in healthy controls ( $n = 9$ ), SLE patients before intravenous pulse ( $n = 26$ ) and at day 1 ( $n = 1$ ) and day 8 after the pulse ( $n = 2$ ). Bottom: PDCs frequency in the CD11c population patients before intravenous pulse (D0,  $n = 10$ ) and at day 1 ( $n = 9$ ) and day 6 after pulse ( $n = 2$ ). Data are plotted as mean  $\pm$  s.e.m.

©2010 Macmillan Publishers Limited. All rights reserved



**Figure 2 | Glucocorticoids do not affect viability of TLR7- and TLR9-activated PDCs because of its lack of activity on TLR-induced NF-κB activation.** **a–d**, Purified PDCs were grown in medium (Med) or as indicated and viability was assessed after 24 h. **a**, Average of 6–12 independent donors is shown ± s.e.m. \*\*  $P \leq 0.01$ . TLR7 (TLR ligand) alone versus grown with IRS. **b**, PDCs were grown with glucocorticoids (10<sup>-5</sup> M) either alone or as indicated. Average of 5–8 independent donors ± s.e.m. is shown. **c**, PDCs were grown with CpG-C either alone or with inhibitors of p38 MAPK (SB, SB203580), PI-3 kinase (LY, LY294002) or NF-κB (IKK-2 IV, p50 or NEMO inhibitory peptides). Average of 6–8 independent donors ± s.e.m. is shown. **e–g**, Nuclear extracts from purified PDCs (**e**, **f**) or monocytes (**g**) were prepared following cultures as indicated and the transcriptional activity of NF-κB was assessed. IKK-2 was used at 0.5 μM. Data are shown as OD values based on absorbance at 450 nm (mean ± s.e.m.) of at least four independent experiments.

glucocorticoids to interfere with the NF-κB pathway in PDCs may explain why TLR-activated PDCs are resistant to glucocorticoid-mediated death.

We next investigated the effect of glucocorticoids on PDCs in mouse models *in vivo*. In normal mice, PDCs were extremely sensitive to glucocorticoid treatment and promptly disappeared from blood (Fig. 3a) and spleen (Fig. 3b). Other TLR9<sup>+</sup> cell types, including


conventional dendritic cells (cDC) (CD11c<sup>+</sup>) and B cells (B220<sup>+</sup>) were similarly reduced (Fig. 3a, b). In contrast, neutrophils (GR1<sup>+</sup>) were not responsive to glucocorticoid treatment, consistent with observations that glucocorticoids promote survival, not death, of human neutrophils *in vitro*<sup>17</sup>. TLR9 activation *in vivo* with CpG-ISS afforded significant protection from glucocorticoid-induced cell death to conventional and PDCs in both spleen and blood (Fig. 3c, d). Splenic B cells were similarly protected from death by TLR9 activation, but circulating blood B cells were not (Fig. 3c, d). Co-injection of IRS prevented CpG-ISS-induced activation (Supplementary Fig. 4), resulting in increased glucocorticoid-induced cell death in both blood and spleen (Fig. 3c, d). Thus, naive circulating PDCs are significantly more susceptible to glucocorticoid-induced cell death than TLR-activated PDCs *in vivo*.

We studied this phenomenon in a disease model using the lupus-prone mouse strains (NZBxNZW)F<sub>1</sub> and TLR7.Tg.6. The (NZBxNZW)F<sub>1</sub> mice spontaneously develop a disease resembling human SLE with increased nucleic-acid-containing immune complexes. Type I IFNs are associated with development of disease<sup>18–21</sup> and blocking TLR7 and 9 reduced autoantibody titres and end-organ damage<sup>22</sup>. The TLR7.Tg.6 strain displays increased TLR7 expression, accumulation of anti-RNA autoantibodies, upregulation of type I IFN gene signature and an autoimmune syndrome resembling human SLE<sup>23</sup>. Both strains are models of spontaneous autoimmunity due to recognition of endogenous nucleic acids by TLR7 and 9 as in SLE patients.

Confirming our hypothesis, TLR7 and 9 bearing cells such as PDCs, cDCs and B cells were significantly more resistant to glucocorticoid-induced death in lupus-prone mice compared to normal strains such as 129 or C57BL/6, in which 0.5 mg glucocorticoids induced a 50–75% reduction in live PDCs (Fig. 4a, b). In both lupus strains, as in SLE patients, chronically activated cells thus have a reduced response to glucocorticoid treatment. Blocking TLR7 and 9 *in vivo* with IRS 954 enhanced the sensitivity to glucocorticoids of PDCs, cDCs and B cells in both spleen (Fig. 4c, d) and blood (Supplementary Fig. 5a, b). The expansion of neutrophils after glucocorticoid treatment (Supplementary Fig. 5a, b) is consistent with the expansion of granulocytes in mice and humans following glucocorticoid administration<sup>12,24–26</sup> and with the persistence of a low density neutrophil gene signature after high dose steroids in SLE patients<sup>27</sup>. Interestingly, we observed a reduction of the glucocorticoid-induced neutrophil expansion after IRS administration (Supplementary Fig. 5a, b) perhaps indicating that blocking TLR7 and 9 could have an impact on the dysregulated granulopoiesis in SLE. Inhibition of TLR7 and 9 was similar in both lupus-prone mouse strains and specific for nucleic acid-induced inflammation as (1) IRS do not induce cell death without glucocorticoids (Supplementary Fig. 6a, b), (2) blocking TLR7 and 9 has no effect on PDCs in normal mice injected with glucocorticoids (Supplementary Fig. 6c) and (3) PDCs from young (NZBxNZW)F<sub>1</sub> mice (before disease onset) were more sensitive to glucocorticoids than PDCs from older mice (Supplementary Fig. 6d). The increased glucocorticoid activity in mice pre-treated with IRS was significant at glucocorticoid doses that had no effect on PDC survival in normal mice (Supplementary Fig. 7a). These findings support the hypothesis that innate inflammation through self nucleic acid recognition is a dominant feature in the unresponsiveness of SLE patients to glucocorticoid treatment. As observed in human SLE, type I IFN-regulated genes are stimulated to some extent in both (NZBxNZW)F<sub>1</sub> and TLR7.Tg.6 model<sup>18,23</sup>. In both lupus-prone strains, IRS pre-treatment reduced the expression of IFN-regulated genes but not TNF-α (Supplementary Fig. 7b, c), demonstrating that activation through TLR7 and 9 is central to inflammation in these mice.


SLE is a complex autoimmune disease and the evaluation of new drugs has proven difficult even for therapeutics approved for other autoimmune diseases. The possibility to reduce glucocorticoid doses in patients while maintaining its cytotoxic activity on PDCs offers significant promise. We show here that the chronic stimulation of





**Figure 3 | TLR9 activation *in vivo* renders PDCs more resistant to glucocorticoid treatment.** **a, b**, 129 mice had no treatment (No Tx) or were injected with graded doses of dexamethasone and cells prepared from blood (**a**) or spleens (**b**) after 18 h. In blood (**a**), data are expressed as number of cells per ml of blood and as total number of cells in spleens (**b**).  $n = 6$  mice per group. **c, d**, 129 mice were either left untreated or treated with 1 mg

dexamethasone alone or in the presence of either CpG-C ISS (50  $\mu$ g per mouse) or with CpG-C ISS plus IRS (100  $\mu$ g per mouse). Number of cells per ml in blood is shown in (**c**) and total number of cells in spleen is shown in (**d**). Cumulative data of two independent experiments;  $n = 8$  mice per group is shown. Plotted data represent averages  $\pm$  s.e.m. \*\*  $P \leq 0.01$ , \*\*\*  $P \leq 0.001$ .



PDCs through TLR7 and 9 by circulating self nucleic acid-containing autoantibodies results in the induction of type I IFN, but additionally in the reduced therapeutic activity of glucocorticoids. This provides novel understanding of the role of self recognition of DNA and RNA by TLR as an important inflammatory amplifier in SLE. These data also stress the potential use of bi-functional TLR7 and 9 inhibitors such as IRS as corticosteroid-sparing drugs.

## METHODS SUMMARY

**Reagents.** Phosphorothioate oligodeoxynucleotides (ODNs) (CpG-C ISS (C274) as TLR9 ligand and IRS 954 as inhibitor of TLR7 and TLR9, ref. 11) were prepared as described previously<sup>28</sup>. Heat-inactivated influenza virus (H1N1, strain A/PR/8/34) was obtained from ATCC. Hydrocortisone and dexamethasone (DEX) were purchased from Sigma. Purification of anti-RNP immune complex was performed as described previously<sup>11</sup>.

**Patients and healthy donors.** Paediatric patients were recruited at Baylor University Medical Center, Texas Scottish Rite Hospital, and Children's Medical Center, all in Dallas, Texas, USA. The study was approved by the institutional review board of all three institutions. Informed consents were obtained from all patients (legal representatives and patients over 10 years of age). The demographic characteristics of 71 SLE patients are displayed in Supplementary Table 2. Blood samples were analysed by flow cytometry using standard techniques.

**Figure 4 | PDCs from lupus-prone mice have intrinsic resistance to glucocorticoid-induced cell death compared to normal mice because of TLR7 and 9 activation by self-nucleic acid.** **a, b**, Normal (closed symbols) and lupus-prone (open symbols) animals were either left untreated or treated with dexamethasone (GC). Cell numbers in blood (**a**, fold change to pre-bleed) and spleens (**b**, fold change to untreated) was assessed 18 h later. Cumulative data of at least three independent experiments is shown. \*\*\*  $P \leq 0.001$  indicate differences between both lupus strains from either normal strains. 129 and B6, normal mice; TLR7 and NZB, lupus-prone mice. **c, d**, (NZBxNZW)<sub>F1</sub> and TLR7.Tg.6 mice (**c** and **d**, respectively) were left untreated or treated with glucocorticoids alone or in the presence of IRS or control (CTRL) ODN (100  $\mu$ g per mouse sub-cutaneously) given every 3 days for 10 days before the glucocorticoid treatment. Viability was assessed in the spleen 18 h after DEX. Cumulative data of two independent experiments is shown.

A set of transcriptional modules (Supplementary Table 1) was used as a framework for the analysis of microarray data as reported previously<sup>10</sup>. In some cases, we used the nCounter Analysis System (NanoString Technologies) as described previously<sup>29</sup>.

**Isolation and *in vitro* stimulation of purified PDCs and measurement of cell survival.** Buffy coats were obtained from the Stanford Blood Center and cells were used under internal Institutional Review Board-approved protocols. PDCs were isolated as previously described<sup>30</sup>. For assessing the viability of PDCs, we used flow cytometry and the Invitrogen “live or dead cell viability kit” according to manufacturer instructions.

**Treatment of mice and cellular analysis.** Mice used were 8–12-weeks-old C57BL/6 and 129 mice as well as 16–17-weeks-old (NZBxNZW)F<sub>1</sub> female and the recently described TLR7.6 transgenic mice overexpressing TLR7 (ref. 23) used at 8 weeks of age. Mice were analysed after 18 h from DEX administration by flow cytometry using standard techniques and gene expression was performed using real-time quantitative PCR (TaqMan) analysis.

**Full Methods** and any associated references are available in the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

**Received 20 November 2009; accepted 21 April 2010.**

- Hahn, B. H. Antibodies to DNA. *N. Engl. J. Med.* **338**, 1359–1368 (1998).
- Chatham, W. W. & Kimberly, R. P. Treatment of lupus with corticosteroids. *Lupus* **10**, 140–147 (2001).
- Franchin, G. & Diamond, B. Pulse steroids: how much is enough? *Autoimmun. Rev.* **5**, 111–113 (2006).
- Parker, B. J. & Bruce, I. N. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. *Lupus* **16**, 387–393 (2007).
- De Bosscher, K., Vanden Berghe, W. & Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor- $\kappa$ B or activator protein-1: molecular mechanisms for gene repression. *Endocr. Rev.* **24**, 488–522 (2003).
- Barrat, F. J. & Coffman, R. L. Development of TLR inhibitors for the treatment of autoimmune diseases. *Immunol. Rev.* **223**, 271–283 (2008).
- Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. *Immunity* **25**, 383–392 (2006).
- Wenzel, J. & Tüting, T. An IFN- $\alpha$ -associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in “interface dermatitis”. *J. Invest. Dermatol.* **128**, 2392–2402 (2008).
- Tucci, M. *et al.* Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. *Arthritis Rheum.* **58**, 251–262 (2008).
- Chaussabel, D. *et al.* A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. *Immunity* **29**, 150–164 (2008).
- Barrat, F. J. *et al.* Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. *J. Exp. Med.* **202**, 1131–1139 (2005).
- Shodell, M., Shah, K. & Siegal, F. P. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. *Lupus* **12**, 222–230 (2003).
- Montague, J. W. & Cidlowski, J. A. Glucocorticoid-induced death of immune cells: mechanisms of action. *Curr. Top. Microbiol. Immunol.* **200**, 51–65 (1995).
- Boor, P. P. *et al.* Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. *Am. J. Transplant.* **6**, 2332–2341 (2006).
- Takauji, R. *et al.* CpG-DNA-induced IFN- $\alpha$  production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. *J. Leukoc. Biol.* **72**, 1011–1019 (2002).
- Guiducci, C. *et al.* PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid dendritic cells in response to TLR activation. *J. Exp. Med.* **205**, 315–322 (2008).
- Strickland, I. *et al.* High constitutive glucocorticoid receptor  $\beta$  in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. *J. Exp. Med.* **193**, 585–594 (2001).
- Rozzo, S. J. *et al.* Evidence for an interferon-inducible gene, *Ifi202*, in the susceptibility to systemic lupus. *Immunity* **15**, 435–443 (2001).
- Santiago-Raber, M. L. *et al.* Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. *J. Exp. Med.* **197**, 777–788 (2003).
- Mathian, A., Weinberg, A., Gallegos, M., Banchereau, J. & Koutouzov, S. IFN- $\alpha$  induces early lethal lupus in preautoimmune (New Zealand Black  $\times$  New Zealand White)F<sub>1</sub> but not in BALB/c mice. *J. Immunol.* **174**, 2499–2506 (2005).
- Agrawal, H. *et al.* Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. *J. Immunol.* **183**, 6021–6029 (2009).
- Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C. & Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. *Eur. J. Immunol.* **37**, 3582–3586 (2007).
- Deane, J. A. *et al.* Control of Toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. *Immunity* **27**, 801–810 (2007).
- Athens, J. W. *et al.* Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. *J. Clin. Invest.* **40**, 989–995 (1961).
- Laakko, T. & Fraker, P. Rapid changes in the lymphopoietic and granulopoietic compartments of the marrow caused by stress levels of corticosterone. *Immunology* **105**, 111–119 (2002).
- Trottier, M. D., Newsted, M. M., King, L. E. & Fraker, P. J. Natural glucocorticoids induce expansion of all developmental stages of murine bone marrow granulocytes without inhibiting function. *Proc. Natl Acad. Sci. USA* **105**, 2028–2033 (2008).
- Bennett, L. *et al.* Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. *J. Exp. Med.* **197**, 711–723 (2003).
- Duramad, O. *et al.* Inhibitors of TLR-9 act on multiple cell subsets in mouse and man *in vitro* and prevent death *in vivo* from systemic inflammation. *J. Immunol.* **174**, 5193–5200 (2005).
- Geiss, G. K. *et al.* Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nature Biotechnol.* **26**, 317–325 (2008).
- Guiducci, C. *et al.* Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. *J. Exp. Med.* **203**, 1999–2008 (2006).

**Supplementary Information** is linked to the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

**Acknowledgements** We would like to thank A. O’Garra, G. Trinchieri, J.-L. Casanova and our colleagues at Dynavax Technologies for their critical reading of the manuscript. We thank S. Noonan and H. Lopez (Murigenics) for invaluable assistance with animal work. This work was supported by NIH grants P50-AR054083-01CORT, U19-AI082715-01, The Alliance for Lupus Research, The Mary Kirkland Foundation (to V.P.) and SBIR grant 2R44AI066483-02 (to R.L.C.).

**Author Contributions:** C.G. and F.J.B. designed the study; C.G., M.Go., Z.X., M.Gi., T.M. and J.H.C. performed experiments; D.C., V.P., C.G. and F.J.B. collected and analysed data; S.B. provided the mice; T.W. and M.P. followed the cohort of patients and provided clinical samples; C.G., Z.X., R.L.C., V.P. and F.J.B. wrote the manuscript; V.S., J.B. and R.L.C. gave conceptual advice.

**Author Information** Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare competing financial interests: details accompany the full-text HTML version of the paper at [www.nature.com/nature](http://www.nature.com/nature). Readers are welcome to comment on the online version of this article at [www.nature.com/nature](http://www.nature.com/nature). Correspondence and requests for materials should be addressed to F.J.B. ([fbarrat@dynavax.com](mailto:fbarrat@dynavax.com)).

## METHODS

**Reagents.** Phosphorothioate ODNs were prepared as described previously<sup>28</sup>. The prototype for ISS class C used was: CpG-C (C274): 5'-TCGTCGAACGTTTC GAGATGAT-3'. The prototype for inhibitor of TLR7 and 9 used was IRS 954, 5'-TGCTCCTGGAGGGTGTGT-3' (ref. 11). Control oligonucleotide was 5'-TCCTGCAGGTAAAGT-3'. Heat-inactivated influenza virus (H1N1, strain A/PR/8/34) was obtained from ATCC. Hydrocortisone and dexamethasone were purchased from Sigma. Purification of anti-RNP-IC was performed as described previously<sup>11</sup>. Human IFN- $\alpha$  ELISA set were purchased from PBL Biomedical Laboratories. PI-3 kinase inhibitor LY294002 (LY), p38 MAPK inhibitors SB203580 and p38 MAPK III, and NF- $\kappa$ B inhibitor (IKK-2 IV) were purchased from Calbiochem. P50 and NEMO inhibitory peptides were purchased from Imgenex.

**Patients and healthy donors.** Paediatric patients were recruited at Baylor University Medical Center, Texas Scottish Rite Hospital, and Children's Medical Center, all in Dallas, Texas, USA. The study was approved by the institutional review board of all three institutions. Informed consents were obtained from all patients (legal representatives and patients over 10 years of age). The demographic characteristics of 71 SLE patients are displayed in Supplementary Table 2. Briefly, they were 85% females, 15% males; 42% Hispanic, 32% African Americans, 15% White. The average patient age was  $14.1 \pm 2.4$  years. The average SLE disease activity index (SLEDAI) was  $8.2 \pm 6.1$ . Forty one healthy age- and ethnicity-matched children were included in microarray and nanostring experiments as controls.

**Blood sample collection.** Blood samples for gene expression analysis were collected in Tempus tubes and immediately delivered to Baylor Institute for Immunology Research at room temperature and stored at  $-20^\circ\text{C}$  before processing. For flow cytometry analysis, 100  $\mu\text{l}$  of blood and 3–10  $\mu\text{l}$  of each antibody were incubated for 30 min. The blood was then lysed with FACS Lysing Solution (BD Biosciences), rinsed with PBS, centrifuged at 300g for 10min, and resuspended in 1% paraformaldehyde. Samples were then acquired on a FACSCalibur flow cytometer and analysed with CellQuest software (BD Biosciences). The following fluorochrome-conjugated anti-human antibodies were used for whole-blood staining: LINEAGE–fluorescein isothiocyanate (FITC) cocktail (containing CD3, CD14, CD16, CD19, CD20 and CD56), CD123–phycoerythrin (PE), HLA-DR–peridinin chlorophyll protein (PerCP), CD11c–allophycocyanin (APC), CD4–FITC, CD8–PE, CD3–PerCP, and CD14–APC (BD Biosciences).

**Modular analysis.** A set of transcriptional modules was used as a framework for the analysis of microarray data. The approach used for the construction of such framework was reported previously<sup>10</sup>. Briefly, genes with coordinate expression within or across whole-blood data sets corresponding to nine human diseases were selected in multiple rounds of clique and paraclique clustering to form a transcriptional module framework. Ingenuity Pathway Analysis (IPA) (Ingenuity Systems), PubMed and iHOP databases were used for module annotation and functional analysis. Module expression level is defined as the average normalized data for all the genes in the module (supplemental Table 1). Colour intensity indicates the proportion of genes within each module that are expressed at significantly different levels in SLE patients. Red, overexpressed; blue, under-expressed. Expression was normalized to an age- and ethnicity-matched control group ( $n = 9$ ).

**NanoString nCounter assay.** The details of the nCounter Analysis System (NanoString Technologies) were described previously<sup>29</sup>. The nCounter code set include 240 genes of interest and 20 control genes. Samples were hybridized using 100 ng of total RNA. The expression levels of each gene were normalized to those of 20 control genes.

**Isolation and *in vitro* stimulation of purified PDCs and measurement of cell survival.** Buffy coats were obtained from the Stanford Blood Center and cells

were used under internal Institutional Review Board-approved protocols or from adult healthy donors (Saint-Antoine Crozatier Blood Bank, Paris, France) where all donors signed informed consent to allow the use of their blood for research purposes. PDCs were isolated either by using positive selection using BDCA-4-conjugated beads or by using negative depletion (Miltenyi Biotech) as described previously<sup>30</sup>. PDCs were 94–99% BDCA<sup>2+</sup> CD123<sup>+</sup> as determined by flow cytometry. For viability  $1 \times 10^5$  PDCs were stimulated in 96-well plates with CpG-C (0.5  $\mu\text{M}$ ), or FLU (2 multiplicities of infection) in the presence of different doses of hydrocortisone. Alternatively,  $1 \times 10^5$  PDCs were grown with 50,000 ultraviolet-irradiated (60 mJ) U937 cells in the presence of 0.5  $\text{mg ml}^{-1}$  of purified IgG from anti-RNP-positive SLE patients<sup>11</sup>. When indicated, soluble IFN- $\alpha$  was used at 20  $\text{ng ml}^{-1}$  and blocking IFN was achieved using a combination of anti-IFN- $\alpha$  (5,000 neutralizing U  $\text{ml}^{-1}$ ), anti-IFN- $\beta$  (2,000 neutralizing U  $\text{ml}^{-1}$ ) and mouse anti-IFN- $\alpha/\beta$  receptor MAb (20  $\mu\text{g ml}^{-1}$ ). Cell survival was assessed at 24–48 h by flow cytometry using Invitrogen “live or dead cell viability kit” according to manufacturer instructions.

**Measurement of NF- $\kappa$ B transcriptional activity.** Untouched naive PDCs were purified using the PDC negative selection kit from Miltenyi Biotech and stimulated for 3 h as indicated. Alternatively monocytes were purified from human blood using CD14-conjugated beads (Miltenyi Biotech) and stimulated as indicated for 1 h. Nuclear extracts were prepared using an Active Motif nuclear extraction kit according to manufacturer instructions. Nuclear extracts (2  $\mu\text{g}$ ) were analysed for the binding activity of NF- $\kappa$ B p65 subunit using TransAM NF- $\kappa$ B kit (Active Motif) according to manufacturer instructions.

**Treatment of mice and cellular analysis.** 8–12-weeks-old C57BL/6 and 129 mice were purchased from Charles River. We purchased (NZBxNZW)<sub>F1</sub> female mice from Jackson laboratories and used at 16–17 weeks of age. In some experiments (NZBxNZW)<sub>F1</sub> female mice were used at 3 weeks of age. TLR7.6 transgenic mice overexpressing TLR7 (C57BL/6 background) were previously described<sup>23</sup> and used at 8 weeks of age. Mice were pre-bled in the morning and immediately treated with intraperitoneal glucocorticoid (dexamethasone, Sigma). In some experiments DEX (intraperitoneal) was combined with TLR7 and 9 inhibitors (IRS; sub-cutaneous) as specified in figure legends. We analysed mice 18 h after DEX administration. We performed flow cytometric analyses using fluorochrome-conjugated monoclonal antibodies to mouse CD3, CD11b, GR1, B220, CD11c (BD bioscience), PDCA1 (Miltenyi Biotech) and 120G8 (Invitrogen). Specific gating was done as follow: PDCs were CD11c low, B220<sup>+</sup>, GR1<sup>+</sup>, PDCA1<sup>+</sup>; conventional dendritic cells were CD11c high B220<sup>+</sup>; B cells were B220<sup>+</sup>; T cells were CD3<sup>+</sup>; granulocytes GR1<sup>+</sup>. For quantification of cellular subsets in the spleen collagenase D-treated splenocytes suspension were counted before performing flow cytometric analysis and total number of specific subsets was calculated as a percentage. Absolute cell numbers in blood was calculated by adding an internal microsphere counting standard to the flow cytometry samples (CountBright counting beads; Invitrogen).

**Real-time quantitative PCR (TaqMan) analysis.** PCR reactions were performed as described previously<sup>11</sup>. In brief, RNA was extracted from collagenase D-treated splenocyte suspensions using the Qiagen RNA kit and cDNA was generated with SuperScript First-Strand Synthesis System (Invitrogen). Gene expression levels were calculated based on relative threshold cycle ( $C_t$ ) values. This was done using the formula  $\text{Relative } C_t = 10^5 \times 1.8^{(HSK - GENE)}$ , where HSK is the mean  $C_t$  of triplicate housekeeping gene runs (we used ubiquitin), GENE is the mean  $C_t$  of duplicate runs of the gene of interest, and  $10^5$  is arbitrarily chosen as a factor to bring all values above 0.

**Statistical analysis.** Data were analysed using a Mann–Whitney U-test (2-tailed Student's  $t$ -test using non parametric criteria for independent samples). All analyses were performed using Prism software (GraphPad Software). Differences were considered significant at a  $P$  level less than 0.05.